Aura Biosciences, Inc. (NASDAQ:AURA) Expected to Earn Q1 2024 Earnings of ($0.45) Per Share

Aura Biosciences, Inc. (NASDAQ:AURAFree Report) – Investment analysts at Leerink Partnrs issued their Q1 2024 earnings estimates for shares of Aura Biosciences in a research note issued to investors on Monday, February 5th. Leerink Partnrs analyst A. Berens anticipates that the company will post earnings per share of ($0.45) for the quarter. The consensus estimate for Aura Biosciences’ current full-year earnings is ($1.80) per share. Leerink Partnrs also issued estimates for Aura Biosciences’ Q2 2024 earnings at ($0.46) EPS, Q3 2024 earnings at ($0.49) EPS and Q4 2024 earnings at ($0.43) EPS.

Several other brokerages have also commented on AURA. JMP Securities decreased their price objective on shares of Aura Biosciences from $21.00 to $19.00 and set a “market outperform” rating for the company in a research report on Friday, November 10th. BTIG Research reduced their price target on shares of Aura Biosciences from $38.00 to $21.00 and set a “buy” rating for the company in a research report on Friday, December 8th.

Check Out Our Latest Stock Report on Aura Biosciences

Aura Biosciences Stock Up 2.5 %

Shares of Aura Biosciences stock opened at $8.20 on Wednesday. The firm has a market capitalization of $313.73 million, a P/E ratio of -4.23 and a beta of 0.30. The company has a 50 day moving average price of $8.39 and a 200 day moving average price of $9.08. Aura Biosciences has a 52 week low of $5.99 and a 52 week high of $13.50.

Aura Biosciences (NASDAQ:AURAGet Free Report) last announced its quarterly earnings data on Thursday, November 9th. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.06.

Insiders Place Their Bets

In other Aura Biosciences news, CFO Julie B. Feder sold 6,609 shares of the firm’s stock in a transaction that occurred on Tuesday, January 23rd. The shares were sold at an average price of $7.64, for a total transaction of $50,492.76. Following the completion of the transaction, the chief financial officer now directly owns 62,991 shares of the company’s stock, valued at approximately $481,251.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, insider Los Pinos Elisabet De sold 15,853 shares of Aura Biosciences stock in a transaction that occurred on Tuesday, January 23rd. The shares were sold at an average price of $7.64, for a total transaction of $121,116.92. Following the completion of the transaction, the insider now directly owns 161,438 shares of the company’s stock, valued at approximately $1,233,386.32. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Julie B. Feder sold 6,609 shares of Aura Biosciences stock in a transaction that occurred on Tuesday, January 23rd. The shares were sold at an average price of $7.64, for a total transaction of $50,492.76. Following the transaction, the chief financial officer now directly owns 62,991 shares of the company’s stock, valued at $481,251.24. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Aura Biosciences

Institutional investors have recently made changes to their positions in the company. Royal Bank of Canada increased its holdings in shares of Aura Biosciences by 192.2% during the 2nd quarter. Royal Bank of Canada now owns 3,866 shares of the company’s stock valued at $47,000 after purchasing an additional 2,543 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of Aura Biosciences by 257.7% during the 3rd quarter. Tower Research Capital LLC TRC now owns 6,604 shares of the company’s stock valued at $59,000 after purchasing an additional 4,758 shares in the last quarter. California State Teachers Retirement System grew its stake in Aura Biosciences by 20.2% in the 1st quarter. California State Teachers Retirement System now owns 8,794 shares of the company’s stock valued at $82,000 after acquiring an additional 1,478 shares during the period. Trexquant Investment LP acquired a new stake in Aura Biosciences in the 3rd quarter valued at $95,000. Finally, Susquehanna International Group LLP acquired a new stake in Aura Biosciences in the 1st quarter valued at $96,000. 70.87% of the stock is owned by hedge funds and other institutional investors.

Aura Biosciences Company Profile

(Get Free Report)

Aura Biosciences, Inc operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for treating tumors of high unmet need in ocular and urologic oncology. It is developing AU-011, a VDC candidate for the treatment of primary choroidal melanoma that is in phase III clinical trial.

See Also

Earnings History and Estimates for Aura Biosciences (NASDAQ:AURA)

Receive News & Ratings for Aura Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aura Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.